MX2024008557A - Método de administración de upadacitinib para evitar interacciones farmacologicas y efectos adversos. - Google Patents
Método de administración de upadacitinib para evitar interacciones farmacologicas y efectos adversos.Info
- Publication number
- MX2024008557A MX2024008557A MX2024008557A MX2024008557A MX2024008557A MX 2024008557 A MX2024008557 A MX 2024008557A MX 2024008557 A MX2024008557 A MX 2024008557A MX 2024008557 A MX2024008557 A MX 2024008557A MX 2024008557 A MX2024008557 A MX 2024008557A
- Authority
- MX
- Mexico
- Prior art keywords
- upadacitinib
- administering
- effects
- drug interactions
- adverse drug
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263299324P | 2022-01-13 | 2022-01-13 | |
| US202263320149P | 2022-03-15 | 2022-03-15 | |
| PCT/US2023/060648 WO2023137440A2 (en) | 2022-01-13 | 2023-01-13 | Method of administering upadacitinib to avoid adverse drug interactions and effects |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024008557A true MX2024008557A (es) | 2024-09-11 |
Family
ID=87279802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024008557A MX2024008557A (es) | 2022-01-13 | 2023-01-13 | Método de administración de upadacitinib para evitar interacciones farmacologicas y efectos adversos. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230233555A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4463161A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2025502266A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20240148324A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2023206381A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3246767A1 (cg-RX-API-DMAC10.html) |
| MX (1) | MX2024008557A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023137440A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12365689B2 (en) | 2015-10-16 | 2025-07-22 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| CN116270646A (zh) | 2015-10-16 | 2023-06-23 | 艾伯维公司 | 制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法 |
| US12570664B2 (en) | 2015-10-16 | 2026-03-10 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11564922B2 (en) * | 2017-03-09 | 2023-01-31 | Abbvie Inc. | Methods of treating crohn's disease and ulcerative colitis |
| CN110392572A (zh) * | 2017-03-09 | 2019-10-29 | 艾伯维公司 | 治疗克罗恩病和溃疡性结肠炎的方法 |
| US10857144B2 (en) * | 2017-05-16 | 2020-12-08 | Bow River LLC | Methods of treatment |
-
2023
- 2023-01-13 MX MX2024008557A patent/MX2024008557A/es unknown
- 2023-01-13 CA CA3246767A patent/CA3246767A1/en active Pending
- 2023-01-13 KR KR1020247024707A patent/KR20240148324A/ko active Pending
- 2023-01-13 WO PCT/US2023/060648 patent/WO2023137440A2/en not_active Ceased
- 2023-01-13 JP JP2024541996A patent/JP2025502266A/ja active Pending
- 2023-01-13 EP EP23740880.2A patent/EP4463161A4/en active Pending
- 2023-01-13 AU AU2023206381A patent/AU2023206381A1/en active Pending
- 2023-03-28 US US18/127,211 patent/US20230233555A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025502266A (ja) | 2025-01-24 |
| WO2023137440A3 (en) | 2023-10-05 |
| EP4463161A4 (en) | 2026-01-14 |
| US20230233555A1 (en) | 2023-07-27 |
| KR20240148324A (ko) | 2024-10-11 |
| EP4463161A2 (en) | 2024-11-20 |
| AU2023206381A1 (en) | 2024-07-25 |
| WO2023137440A2 (en) | 2023-07-20 |
| CA3246767A1 (en) | 2023-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2023137440A3 (en) | Method of administering upadacitinib to avoid adverse drug interactions and effects | |
| Wickramaratneb | Serotonergic anxiolytics and treatment of depression | |
| KR101941004B1 (ko) | 조절 t 세포로의 분화 유도 및 증식 촉진을 통한 면역 반응 억제용 약학 조성물 | |
| Kavand et al. | Cutaneous manifestations of graft‐versus‐host disease: role of the dermatologist | |
| Rengachary et al. | Structural changes in human pituitary tumor after bromocriptine therapy | |
| EP1196167A1 (en) | Method of reducing neuronal injury or apoptosis | |
| CN1187045C (zh) | 用于治疗牛皮癣的物质 | |
| Ishida et al. | Comparison of outcomes for pediatric patients with acute myeloid leukemia in remission and undergoing allogeneic hematopoietic cell transplantation with myeloablative conditioning regimens based on either intravenous busulfan or total body irradiation: a report from the Japanese Society for Hematopoietic Cell Transplantation | |
| US11673965B2 (en) | Method of treating metastatic triple negative breast cancer with radiotherapy combined with phosphatidyl inositol-3 kinase delta/gamma inhibitors and anti-PD-1 antibodies | |
| JP2019059748A (ja) | 移植患者における移植片対宿主病の治療 | |
| WO2022026900A3 (en) | Nk receptor antagonists for cancer patients | |
| MX2025000673A (es) | Metodos de administracion de nalbufina | |
| WO2022241151A3 (en) | Chimeric antigen receptor t cell therapy | |
| WO2023141609A3 (en) | Treatment of inflammatory disorders | |
| Li et al. | Neurod1 modulates opioid antinociceptive tolerance via two distinct mechanisms | |
| MX2024009972A (es) | Terapias combinadas para el tratamiento del cancer que comprenden un conjugado de farmaco anticuerpo b7-h4. | |
| CR20220531A (es) | Modulacion de enzimas y vías con compuestos de sulfhidrilo y sus derivados | |
| WO2023113843A3 (en) | Borylated di-peptide amino acid compositions for use in boron neutron capture therapy and methods thereof | |
| CN103417971A (zh) | 二肽基肽酶抑制剂和b族维生素的药物组合物及用途 | |
| MX2024005374A (es) | Metodos para tratar la enfermedad de celulas falciformes con voxelotor. | |
| Beltagy et al. | Role of harmaline as adiponectin modulator in defeating liver cirrhosis induced by thioacetamide in mice | |
| CN116236488A (zh) | 一叶秋碱在制备治疗早发性卵巢功能不全及卵巢响应匮乏药物中的应用 | |
| Samad et al. | Behavioral and neurochemical profile of m-CPP following exposure to single restraint stress in rat. | |
| WO2007011960A3 (en) | Methods and agents to treat autoimmune diseases | |
| WO2023169357A1 (en) | Methods for treating immune diseases |